Prompt repeat testing after out-of-range INR values: a quality indicator for anticoagulation care

Circ Cardiovasc Qual Outcomes. 2011 May;4(3):276-82. doi: 10.1161/CIRCOUTCOMES.110.960096. Epub 2011 Apr 19.

Abstract

Background: Improved control of oral anticoagulation reduces adverse events. A program of quality measurement is needed for oral anticoagulation. The interval until the next test after an out-of-range International Normalized Ratio (INR) value (the "follow-up interval") could serve as a process of care measure.

Methods and results: We studied 104 451 patients cared for by 100 anticoagulation clinics in the Veterans Health Administration (VA). For each site, we computed the average follow-up interval after low (≤1.5) or high (≥4.0) INR. Our outcome was each site's average anticoagulation control, measured by percent time in therapeutic range (TTR); 59 837 patients (57%) contributed to the low INR analysis, 37 697 (36%) contributed to the high INR analysis, and all patients contributed to the dependent variable (mean site TTR). After a low INR, site mean follow-up interval ranged from 10 to 24 days. Longer follow-up intervals were associated with worse site-level control (1.04% lower for each additional day, P<0.001). After a high INR, site mean follow-up interval ranged from 6 to 18 days, with longer follow-up intervals associated with worse site-level control (1.12% lower for each additional day, P<0.001). These relationships were somewhat attenuated but still highly statistically significant when the proportion of INR values in-range was used as the dependent variable rather than TTR.

Conclusions: Prompt repeat testing after out-of-range INR values is associated with better anticoagulation control at the site level and could be an important part of a quality improvement effort for oral anticoagulation.

Publication types

  • Multicenter Study
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Administration, Oral
  • Aged
  • Anticoagulants / adverse effects*
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / drug therapy*
  • Female
  • Follow-Up Studies
  • Hemorrhage / epidemiology
  • Hemorrhage / prevention & control
  • Humans
  • International Normalized Ratio / methods*
  • Male
  • Middle Aged
  • Quality Indicators, Health Care*
  • Reference Values
  • Retrospective Studies
  • Risk Factors
  • Time Factors
  • United States
  • United States Department of Veterans Affairs
  • Venous Thromboembolism / drug therapy*

Substances

  • Anticoagulants